Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Critical Control Point Model In PAT Guidance Supported By Industry

This article was originally published in The Tan Sheet

Executive Summary

FDA should adopt a critical control point model requiring firms only maintain data that pertain to significant manufacturing stages when drafting its Process Analytical Technology guidance, industry reps suggest

You may also be interested in...

PAT Guidance Will Draw From Existing Electronic Records Guidances

FDA plans to draw from existing guidances to clarify 21 CFR Part 11 electronic record/electronic signature requirements in its planned PAT guidance

FDA Risk-Based Part 11 Proposal Expected By February 2003

FDA intends to issue a policy statement on how its risk-based Good Manufacturing Practices initiative will affect 21 CFR Part 11 - the electronic records and electronic signatures reg - by early next year

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts